Smith & Nephew (NYSE:SNN) said to day that it acquired the BST-CarGel cartilage repair line from Piramal Healthcare for an undisclosed amount.
BST-CarGel, which is approved in Australia, Canada and most of Europe, is a biopolymer-based solution that’s mixed with a patient’s blood and implanted into the knee, hip, ankle or shoulder after microfracture procedures, London-based Smith & Nephew said. It’s designed to act as a scaffold, adhering to cartilage to stabilize the blood clot while new cartilage is built.
“BST-CarGel augments our existing joint repair portfolio with a new option that is differentiated with strong clinical evidence and targets an area of significant patient need and surgeon demand,” sports medicine vice president Scott Schaffner said in prepared remarks. “We are committed to seeking and investing in next-generation technologies to widen access across our global customer base.”
Earlier this month, Smith & Nephew closed its $275 million acquisition of Blue Belt Technologies and its Navio robot-assisted knee replacement platform.
